Celebrating Launch of U.S. Study and 10 Years as NASDAQ Company CEO, CFO and Medical Director Available for Media Interviews

LYON, France , May 25, 2011 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced two abstracts supporting the Ablatherm ® High Intensity Focused Ultrasound's (HIFU) efficacy for the treatment of localized prostate cancer will be featured at the

  AUA is the largest annual gathering of urologists worldwide LYON, France, May 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company will be showcasing and exhibiting its Focal One® Robotic High Intensity

Additional HIFU Data Presented at Engineering and Urology Society Annual Meeting

LYON, France , July 30, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration's (FDA) Gastroenterology and Urology Devices Panel (GUDP) voted 3 yes, 5 no with 1 abstention on the question of

LYON, France , Sept. 22, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that the growing interest in and acceptance of its Ablatherm®-HIFU technology was once again highlighted as a valuable treatment alternative for prostate cancer

Third Long Term Study Published in 2013 Validates Ablatherm-HIFU as First Line Treatment of Prostate Cancer

Longest Retrospective Study of HIFU Patients to Date Published Confirms Benefits of Treatment

LYON, France , May 22, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the U.S. Food and Drug Administration (FDA) Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee will review the Pre-Market

Munich Study Concludes 15 Year Outcome Data May Warrant Closing of Investigational Phase for HIFU